![]() |
Home
Search
Study Topics
Glossary
|
Study 4 of 929 for search of: | Australia, Victoria |
![]() |
Previous Study | Return to Search Results | Next Study |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Human Genome Sciences |
---|---|
Information provided by: | Human Genome Sciences |
ClinicalTrials.gov Identifier: | NCT00115908 |
The purpose of the study is to evaluate the efficacy and safety of Albuferon in combination with ribavirin in interferon (IFN) alfa treatment-naïve subjects with chronic hepatitis C genotype 1. The study will randomize subjects to 1 of 4 treatment groups including 3 different Albuferon groups or to the active control group, peginterferon alfa-2a (PEGASYS, PEG-IFNalfa-2a). All subjects will also receive oral daily ribavirin.
Condition | Intervention | Phase |
---|---|---|
Hepatitis C, Chronic |
Drug: Albuferon/ribavirin Drug: PEG-IFNalfa2a/ribavirin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2b, Randomized, Multi-Center, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 1 |
Estimated Enrollment: | 460 |
Study Start Date: | May 2005 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
Key Exclusion Criteria:
Study Director: | Mani Subramanian, M.D., Ph.D | Human Genome Sciences |
Study ID Numbers: | ALFR-HC-04 |
Study First Received: | June 26, 2005 |
Last Updated: | October 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00115908 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration; Australia: Department of Health and Ageing Therapeutic Goods Administration; Canada: Health Canada; Czech Republic: State Institute for Drug Control; France: Afssaps - French Health Products Safety Agency; Germany: Federal Institute for Drugs and Medical Devices; Poland: Ministry of Health; Romania: State Institute for Drug Control |
Hepatitis C |
Interferon-alpha Virus Diseases Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Chronic |
Interferons Ribavirin Hepatitis, Viral, Human Hepatitis C Interferon Alfa-2a Hepatitis C, Chronic |
Antimetabolites Anti-Infective Agents RNA Virus Infections Molecular Mechanisms of Pharmacological Action Flaviviridae Infections |
Antineoplastic Agents Therapeutic Uses Antiviral Agents Pharmacologic Actions |